Relmada Therapeutics (RLMD) Prepaid Assets (2012 - 2026)
Relmada Therapeutics (RLMD) reported Prepaid Assets of $1.4 million for Q1 2026, up 918.56% year-over-year from $135500.0 in Q1 2025, and up 41.16% on a QoQ basis from $977721.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 14 years of Prepaid Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Prepaid Assets rose 918.56% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 918.56% YoY) and the FY2025 annual result came in at $977721.0, up 10.29% from the prior year.
- Prepaid Assets climbed to $1.4 million in Q1 2026 per RLMD's latest filing, from $977721.0 in the prior quarter.
- Across five years, Prepaid Assets topped out at $5.1 million in Q1 2022 and bottomed at $125000.0 in Q4 2023.
- The 5-year median for Prepaid Assets is $977721.0 (2025), against an average of $1.9 million.
- The widest annual swing landed in 2022, when Prepaid Assets soared 2851.03%; it then slumped 96.9% in 2023.
- Tracing RLMD's Prepaid Assets over 5 years: stood at $4.0 million in 2022, then tumbled by 96.9% to $125000.0 in 2023, then surged by 609.17% to $886461.0 in 2024, then increased by 10.29% to $977721.0 in 2025, then surged by 41.16% to $1.4 million in 2026.
- Per Business Quant, the three latest RLMD Prepaid Assets figures stand at $1.4 million (Q1 2026), $977721.0 (Q4 2025), and $967745.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 977,721.00 |
| Sep 30, 2025 | 967,745.00 |
| Jun 30, 2025 | 307,100.00 |
| Mar 31, 2025 | 135,500.00 |
| Dec 31, 2024 | 886,461.00 |
| Sep 30, 2024 | 611,200.00 |
| Jun 30, 2024 | 537,522.00 |
| Mar 31, 2024 | 752,334.00 |
| Dec 31, 2023 | 125,000.00 |
| Sep 30, 2023 | 2.83 Mn |
| Jun 30, 2023 | 3.47 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 4.04 Mn |
| Sep 30, 2022 | 2.95 Mn |
| Jun 30, 2022 | 3.48 Mn |
| Mar 31, 2022 | 5.06 Mn |
| Dec 31, 2021 | 228,400.00 |
| Sep 30, 2021 | 2.72 Mn |
| Jun 30, 2021 | 1.55 Mn |
| Mar 31, 2021 | 171,600.00 |
| Dec 31, 2020 | 903,190.00 |
| Sep 30, 2020 | 2.25 Mn |
| Jun 30, 2020 | 240,534.00 |
| Mar 31, 2020 | 246,007.00 |
| Dec 31, 2019 | 423,900.00 |
| Sep 30, 2019 | 376,902.00 |
| Jun 30, 2019 | 520,800.00 |
| Mar 31, 2019 | 207,793.00 |
| Dec 31, 2018 | 537,665.00 |
| Sep 30, 2018 | 316,818.00 |
| Jun 30, 2018 | 426,921.00 |
| Mar 31, 2018 | 160,279.00 |
| Dec 31, 2017 | 240,446.00 |
| Sep 30, 2017 | 369,377.00 |
| Jun 30, 2017 | 472,489.00 |
| Mar 31, 2017 | 486,903.00 |
| Dec 31, 2016 | 578,979.00 |
| Sep 30, 2016 | 747,523.00 |
| Jun 30, 2016 | 566,152.00 |
| Mar 31, 2016 | 426,650.00 |
| Dec 31, 2015 | 528,144.00 |
| Sep 30, 2015 | 884,916.00 |
| Jun 30, 2015 | 1.50 Mn |
| Mar 31, 2015 | 857,959.00 |
| Dec 31, 2014 | 1.34 Mn |
| Sep 30, 2014 | 427,622.00 |
| Jun 30, 2014 | 178,158.00 |
| Aug 31, 2012 | 3,000.00 |